Scarica l'app Stockscreener
23.13
0.73%
-0.17
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ROIV Giù?
Forum
Previsione
Precedente Chiudi:
$23.30
Aprire:
$22.8
Volume 24 ore:
8.15M
Relative Volume:
1.03
Capitalizzazione di mercato:
$16.09B
Reddito:
$125.68M
Utile/perdita netta:
$4.81B
Rapporto P/E:
4.0938
EPS:
5.65
Flusso di cassa netto:
$-781.21M
1 W Prestazione:
+5.23%
1M Prestazione:
+0.83%
6M Prestazione:
+100.43%
1 anno Prestazione:
+112.40%
Intervallo 1D:
$22.15
$23.20
Intervallo di 1 settimana:
$21.57
$23.91
Portata 52W:
$8.73
$23.91
Roivant Sciences Ltd Stock (ROIV) Company Profile
Nome
Roivant Sciences Ltd
Settore
Industria
Telefono
441-295-5950
Indirizzo
7TH FLOOR, 50 BROADWAY, LONDON
Confronta ROIV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
23.13 | 16.20B | 125.68M | 4.81B | -781.21M | 5.65 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-02 | Iniziato | Citigroup | Buy |
| 2025-07-10 | Ripresa | Goldman | Buy |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-01-05 | Iniziato | Piper Sandler | Overweight |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-17 | Iniziato | Guggenheim | Buy |
| 2023-06-08 | Iniziato | BofA Securities | Neutral |
| 2022-10-27 | Iniziato | JP Morgan | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-12-15 | Iniziato | Goldman | Buy |
| 2021-11-08 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-28 | Iniziato | Citigroup | Buy |
| 2021-10-26 | Iniziato | Cowen | Outperform |
| 2021-10-26 | Iniziato | Jefferies | Buy |
| 2021-10-26 | Iniziato | Truist | Buy |
Mostra tutto
Roivant Sciences Ltd Borsa (ROIV) Ultime notizie
Roivant Sciences Insider Sold Shares Worth $4,384,000, According to a Recent SEC Filing - marketscreener.com
Roivant Sciences(ROIV.US) Officer Sells US$4.38 Million in Common Stock - 富途牛牛
Roivant Sciences (NASDAQ:ROIV) CEO Eric Venker Sells 200,000 Shares - MarketBeat
Is Roivant Sciences Ltd forming a bullish divergenceJuly 2025 Technicals & Long-Term Growth Stock Strategies - baoquankhu1.vn
Roivant Sciences stock hits all-time high of $23.47 By Investing.com - Investing.com Nigeria
US Market Wrap: Does Roivant Sciences Ltd stock trade at a discount to peers2025 Technical Overview & Stepwise Entry and Exit Trade Signals - Bộ Nội Vụ
Roivant Sciences (NASDAQ:ROIV) Sets New 12-Month HighWhat's Next? - MarketBeat
Discipline and Rules-Based Execution in ROIV Response - Stock Traders Daily
Why Roivant Sciences Ltd. stock could be next big winnerJuly 2025 Sentiment & Low Risk High Reward Ideas - Bộ Nội Vụ
Roivant Sciences stock hits all-time high of $23.47 - Investing.com India
Profit Recap: How risky is Roivant Sciences Ltd stock nowJuly 2025 Highlights & Real-Time Sentiment Analysis - Bộ Nội Vụ
Proxima Raises $80 Million for AI Drug Discovery From DCVA, Nvidia - Bloomberg.com
Roivant Sciences Ltd. (ROIV) Stock Analysis: Exploring a 22.84% Potential Upside in Biotech Innovations - DirectorsTalk Interviews
Buyback Watch: Whats the fair value of Roivant Sciences Ltd stockTrade Ideas & Risk Controlled Daily Plans - baoquankhu1.vn
Published on: 2026-01-10 23:30:08 - Улправда
How Roivant Sciences Ltd. (87S) stock reacts to fiscal policiesJuly 2025 Sentiment & Verified Entry Point Signals - Улправда
What margin trends mean for Roivant Sciences Ltd. stock2025 Historical Comparison & Fast Entry Momentum Trade Alerts - Улправда
Aug Ideas: Can NETGEAR Inc stock maintain operating marginsVolume Spike & Weekly Top Performers Watchlists - moha.gov.vn
Can Roivant Sciences Ltd. stock double in next 5 yearsMarket Performance Summary & Weekly Stock Breakout Alerts - Улправда
How Roivant Sciences Ltd. stock reacts to global recession fears2025 Big Picture & Community Supported Trade Ideas - Улправда
Is Roivant Sciences Ltd. stock positioned for digital transformation2025 Investor Takeaways & Target Return Focused Stock Picks - Улправда
How Roivant Sciences Ltd. stock performs in rate cut cyclesWeekly Market Outlook & Long Hold Capital Preservation Plans - Улправда
Aug Big Picture: How Roivant Sciences Ltd. stock reacts to global recession fearsWeekly Earnings Recap & Real-Time Volume Surge Alerts - ulpravda.ru
What Roivant Sciences (ROIV)'s Accelerated Brepocitinib Push Means For Shareholders - simplywall.st
A Look At Roivant Sciences (ROIV) Valuation After Brepocitinib Timeline Acceleration And Profitability Outlook Shift - simplywall.st
Leerink Partners reiterates Outperform rating on Roivant Sciences stock By Investing.com - Investing.com South Africa
Leerink raises price target as Roivant (ROIV) accelerates drug development pipeline - MSN
Psithera spun out of Roivant with $47.5M and immune, inflammatory focus - BioWorld MedTech
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Penn Davis Mcfarland Inc. Buys 170,456 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Pacer Advisors Inc. Makes New Investment in Roivant Sciences Ltd. $ROIV - MarketBeat
Behavioral Patterns of ROIV and Institutional Flows - Stock Traders Daily
Leerink Raises Price Target as Roivant (ROIV) Accelerates Drug Development Pipeline - Insider Monkey
Roivant Sciences Insider Sold Shares Worth $28,902,500, According to a Recent SEC Filing - MarketScreener
Book value per share of Roivant Sciences Ltd. – DUS:87S - TradingView — Track All Markets
Mayukh Sukhatme Sells 1,018,995 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Mayukh Sukhatme Sells 311,873 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Short Interest in Roivant Sciences Ltd. (NASDAQ:ROIV) Drops By 16.2% - MarketBeat
Insider Selling: Roivant Sciences (NASDAQ:ROIV) CEO Sells 75,000 Shares of Stock - MarketBeat
Richard Pulik Sells 406,731 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Roivant Sciences Executives Engage in Significant Share Sales - TradingView — Track All Markets
Eric Venker Sells 200,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat
Capricorn Fund Managers Ltd Buys New Stake in Roivant Sciences Ltd. $ROIV - MarketBeat
Insider Confidence In December 2025's Leading Growth Companies - Yahoo! Finance Canada
Reassessing Roivant Sciences (ROIV) Valuation After Pipeline Progress, NDA Timelines and Genevant Litigation Updates - simplywall.st
Voya Investment Management LLC Grows Stock Position in Roivant Sciences Ltd. $ROIV - MarketBeat
Is Roivant Sciences Ltd stock positioned for digital transformationGap Down & High Conviction Trade Alerts - moha.gov.vn
Ramaswamy-Backed Ambros Launches with $125M - Orange County Business Journal
Roivant Sciences president Sukhatme sells $619k in shares By Investing.com - Investing.com Australia
Roivant Sciences president Sukhatme sells $619k in shares - Investing.com UK
Roivant Sciences Ltd Azioni (ROIV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Roivant Sciences Ltd Azioni (ROIV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO |
Jan 12 '26 |
Sale |
21.92 |
200,000 |
4,384,000 |
1,654,597 |
4.73%
0.92%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):